Terms: = Brain cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954
136 results:
1. Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract] [Full Text] [Related]
2. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
[TBL] [Abstract] [Full Text] [Related]
3. Clinical trials of R-(-)-gossypol (AT-101) in newly diagnosed and recurrent glioblastoma: NABTT 0602 and NABTT 0702.
Fiveash JB; Ye X; Peerboom DM; Mikkelsen T; Chowdhary S; Rosenfeld M; Lesser GJ; Fisher J; Desideri S; Grossman S; Leopold L; Nabors LB
PLoS One; 2024; 19(1):e0291128. PubMed ID: 38285688
[TBL] [Abstract] [Full Text] [Related]
4. Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
Le Rhun E; Gorlia T; Felsberg J; Jongen J; Maurage CA; Ducray F; Gramatzki D; Hau P; Chinot OL; Preusser M; Cartalat S; Roth P; van den Bent M; Furtner J; Collienne M; Reifenberger G; Weller M
Eur J Cancer; 2024 Feb; 198():113475. PubMed ID: 38159337
[TBL] [Abstract] [Full Text] [Related]
5. The identification of BCL-XL and mcl-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.
Fitzgerald MC; O'Halloran PJ; Kerrane SA; Ní Chonghaile T; Connolly NMC; Murphy BM
Cell Death Dis; 2023 Oct; 14(10):705. PubMed ID: 37898609
[TBL] [Abstract] [Full Text] [Related]
6. Central nervous system involvement by mantle cell lymphoma.
McLaughlin N; Wang Y; Witzig T; Villasboas J; Habermann T; Inwards D; Bennani N; Thanarajasingam G; Nowakowski G; Porrata L; Thompson C; Micallef I; Johnston P; Ansell S; Paludo J
Leuk Lymphoma; 2023 Feb; 64(2):371-377. PubMed ID: 36416595
[TBL] [Abstract] [Full Text] [Related]
7. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
[TBL] [Abstract] [Full Text] [Related]
8. Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma.
Yohannan B; Sridhar A; Nguyen N; Rios A
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35732356
[TBL] [Abstract] [Full Text] [Related]
9. Ursolic acid enhances the antitumor effects of sorafenib associated with mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer.
Li H; Yu Y; Liu Y; Luo Z; Law BYK; Zheng Y; Huang X; Li W
Pharmacol Res; 2022 Aug; 182():106306. PubMed ID: 35714823
[TBL] [Abstract] [Full Text] [Related]
10. Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors.
Parkhurst A; Wang SZ; Findlay TR; Malebranche KJ; Odabas A; Alt J; Maxwell MJ; Kaur H; Peer CJ; Figg WD; Warren KE; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
Cell Death Dis; 2022 Apr; 13(4):410. PubMed ID: 35484114
[TBL] [Abstract] [Full Text] [Related]
11. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics.
Koessinger AL; Cloix C; Koessinger D; Heiland DH; Bock FJ; Strathdee K; Kinch K; Martínez-Escardó L; Paul NR; Nixon C; Malviya G; Jackson MR; Campbell KJ; Stevenson K; Davis S; Elmasry Y; Ahmed A; O'Prey J; Ichim G; Schnell O; Stewart W; Blyth K; Ryan KM; Chalmers AJ; Norman JC; Tait SWG
Cell Death Differ; 2022 Oct; 29(10):2089-2104. PubMed ID: 35473984
[TBL] [Abstract] [Full Text] [Related]
12. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
Nguyen TTT; Shang E; Schiffgens S; Torrini C; Shu C; Akman HO; Prabhu VV; Allen JE; Westhoff MA; Karpel-Massler G; Siegelin MD
Clin Cancer Res; 2022 May; 28(9):1881-1895. PubMed ID: 35417530
[TBL] [Abstract] [Full Text] [Related]
13. brain-Targeted Codelivery of Bcl-2/Bcl-xl and mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy.
He W; Li X; Morsch M; Ismail M; Liu Y; Rehman FU; Zhang D; Wang Y; Zheng M; Chung R; Zou Y; Shi B
ACS Nano; 2022 Apr; 16(4):6293-6308. PubMed ID: 35353498
[TBL] [Abstract] [Full Text] [Related]
14. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
Moujalled D; Southon AG; Saleh E; Brinkmann K; Ke F; Iliopoulos M; Cross RS; Jenkins MR; Nhu D; Wang Z; Shi MX; Kluck RM; Lessene G; Grabow S; Bush AI; Strasser A
Cell Death Differ; 2022 Jul; 29(7):1335-1348. PubMed ID: 35332309
[TBL] [Abstract] [Full Text] [Related]
15. Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.
Huang C; He Y; Sun J; Yuan Q; Li S; Hou H; Su K; Ke C; Du Z; Yuan Z
Acta Histochem; 2022 Feb; 124(2):151856. PubMed ID: 35077998
[TBL] [Abstract] [Full Text] [Related]
16. Non-English Primary Language Is Associated with Short-Term Outcomes After Supratentorial Tumor Resection.
Witt EE; Eruchalu CN; Dey T; Bates DW; Goodwin CR; Ortega G
World Neurosurg; 2021 Nov; 155():e484-e502. PubMed ID: 34461280
[TBL] [Abstract] [Full Text] [Related]
17. SD-36 promotes growth inhibition and induces apoptosis via suppression of mcl-1 in glioma.
Kong S; Ge X; Li X; Liu Z; Zhang R; Yang M; Wang Z; Li Z
J Cell Mol Med; 2021 Sep; 25(17):8261-8270. PubMed ID: 34291563
[TBL] [Abstract] [Full Text] [Related]
18. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.
Boccellato C; Kolbe E; Peters N; Juric V; Fullstone G; Verreault M; Idbaih A; Lamfers MLM; Murphy BM; Rehm M
Cell Death Dis; 2021 Jun; 12(7):647. PubMed ID: 34168123
[TBL] [Abstract] [Full Text] [Related]
19. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
Buzzetti M; Morlando S; Solomos D; Mehmood A; Cox AWI; Chiesa M; D'Alessandra Y; Garofalo M; Topham CH; Di Leva G
Sci Rep; 2021 Mar; 11(1):5374. PubMed ID: 33686114
[TBL] [Abstract] [Full Text] [Related]
20. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Li H; Liu Q; Chen Z; Wu M; Zhang C; Su J; Li Y; Zhang C
Cell Death Dis; 2021 Mar; 12(3):252. PubMed ID: 33674567
[TBL] [Abstract] [Full Text] [Related]
[Next]
